Surgery-Free and Cancer-Gone: What GSK's Jemperli Approval Means for Rectal Cancer Treatment
On October 19, 2026, the FDA granted accelerated approval to GSK's Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III locally advanced rectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). The approval is narrow in scope, applying to a molecular subtype that accounts for only 5 to 10 percent of all rectal cancer cases. But the clinical story behind it is one of the more remarkable in recent oncology, and the implications for how the field thinks about surgery, organ preservation, and the biology of immune-responsive tumors extend well beyond the patient population it immediately serves.
The data that earned this approval began with a small academic study at Memorial Sloan Kettering Cancer Center, led by oncologist Andrea Cercek, that generated headlines in 2022 when every single patient in the initial cohort achieved a complete response to dostarlimab monotherapy. No chemotherapy. No radiation. No surgery. The tumor simply disappeared. That result was striking enough to be dismissed by some as too good to be true, and cautious enough to prompt a larger registrational trial before the FDA would act on it. The AZUR-1 Phase 2 trial enrolled patients globally and measured clinical complete response at 12 months, defined as no detectable signs of cancer for at least one year. The results, now embedded in the FDA's approval, show that 47 percent of 116 evaluable patients met that threshold by independent central review, and 68 percent by investigator assessment. None of the responders have seen their disease return after a median follow-up of more than two years.
What Organ Preservation Actually Means
The standard of care for locally advanced rectal cancer has long been a combination of chemotherapy, radiation, and surgery, a sequence that is often effective but carries lasting consequences. Pelvic radiation can cause bowel dysfunction, urinary complications, and sexual side effects that persist for years. Approximately 30 percent of patients require a permanent colostomy, a surgical procedure that removes a section of the colon or rectum and redirects waste through an opening in the abdomen. For younger patients, the fertility implications are particularly severe: pelvic radiation can induce premature menopause in women, and the surgical disruption of pelvic anatomy affects reproductive function in both sexes.
Cercek noted during a press briefing ahead of the approval that five babies have been born to patients from the initial academic study, including four to two women who, in her words, "100 percent would not have been able to have children due to the location of their tumor" and the standard treatment they would otherwise have received. That detail is not a footnote. It is a direct measure of what this approval means for a population that skews younger than many other cancer types and for whom the collateral damage of conventional treatment has historically been accepted as an unavoidable cost of survival.
The biology that makes this possible is worth understanding. MSI-H and dMMR tumors carry a specific genetic defect: they cannot properly repair DNA damage, which leads to an accumulation of mutations. That accumulation makes the tumor highly visible to the immune system, creating what oncologists call a "hot" tumor, one that is already primed for immune attack. Checkpoint inhibitors like dostarlimab work by releasing the brakes on T cells that would otherwise be suppressed by the tumor's immune evasion mechanisms. In MSI-H/dMMR tumors, those T cells have a great deal to work with. The result, in a meaningful fraction of patients, is a complete and durable elimination of the cancer without any cytotoxic intervention.
The Accelerated Approval Caveat
The FDA's decision was made under the accelerated approval pathway, which means GSK is required to confirm the benefit in a subsequent trial. The ongoing Phase 3 Azur-2 study is evaluating Jemperli used before and after surgery against post-surgical chemotherapy or observation in stage III MSI-H/dMMR resectable colon cancer, with results expected in 2028. That confirmatory requirement is appropriate. The AZUR-1 trial was a single-arm study without a randomized comparator, and the clinical complete response endpoint, while validated and accepted by the FDA, is a surrogate measure rather than a direct demonstration of survival benefit. The absence of recurrence after two-plus years of follow-up is encouraging, but the durability of these responses over longer time horizons remains to be established.
The accelerated approval framework also places Jemperli in a competitive context that will evolve. Roche's Tecentriq recently received FDA clearance as a post-surgical treatment for stage III dMMR colon cancer in combination with chemotherapy, demonstrating a 50 percent improvement in disease-free survival. The two approvals address different settings and different patient populations, but they collectively signal that the MSI-H/dMMR biomarker is becoming a meaningful organizing principle for immunotherapy development across the colorectal cancer spectrum, not just in the metastatic setting where checkpoint inhibitors have been established for years.
The Broader Signal for Biomarker-Driven Oncology
The Jemperli approval is also a data point in a longer argument about how oncology is changing. The traditional model of cancer treatment organized around tumor location, treating rectal cancer as a disease of the rectum rather than as a disease defined by its molecular characteristics, is giving way to a model organized around biology. MSI-H/dMMR status is found across dozens of tumor types, and the FDA has previously granted dostarlimab accelerated approval for dMMR advanced solid tumors broadly. The new rectal cancer approval is more specific, reflecting the particular clinical context of locally advanced disease where the alternative to immunotherapy is not just systemic treatment but life-altering surgery.
That specificity matters for how physicians and patients will use the drug. The approval covers a narrow population, perhaps 2,500 to 5,000 patients annually in the United States given the estimated 50,000 new rectal cancer cases per year and the 5 to 10 percent MSI-H/dMMR prevalence. But for those patients, the availability of an immunotherapy-only approach that can achieve complete responses without chemotherapy, radiation, or surgery represents a genuine transformation in what treatment looks like. The question of whether a complete response on imaging translates into a cure, or whether some patients will eventually recur after longer follow-up, will be answered by the data that accumulate over the coming years. What the AZUR-1 results establish today is that the immune system, properly engaged, can eliminate locally advanced rectal cancer in a substantial fraction of patients who carry the right molecular signature. That is not a minor refinement of existing treatment. It is a different kind of medicine altogether.
